NASDAQ:HCM 实时

13.72 1.19 9.50% 2025-04-11 16:00:00

盘后 13.90 0.18 1.31% 成交量 0.75万 2025-04-11 20:00

Wei Guo Su: Wei Guo Su is currently the CEO, Executive Director & Chief Scientific Officer at HUTCHMED (China) Ltd. since 2022. He is also currently serving as the Chief Scientific Officer & Executive VP at Hutchison MediPharma Ltd. since 2012. Previously, he worked at Pfizer Inc. as the Director-Medicinal Chemistry Department. Dr. Su holds a doctorate degree from Harvard University and an undergraduate degree from Fudan University.

Edith Shih: Edith Shih currently works at Accounting & Financial Reporting Council, as Chairman-Process Review Panel, Maritime Transport Services Ltd., as Director, Port of Felixstowe Ltd., as Director from 1997, and various other companies. Ms. Shih also formerly worked at China Oceanwide Holdings Ltd., as Secretary & Executive Director from 2012 to 2014, VC Capital Ltd., as Director from 1989 to 1991, H3G SpA, as Director, and various other companies. Ms. Shih received her graduate degree from The Trustees of Columbia University in The City of New York and undergraduate degree and graduate degree from the University of the Philippines.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Michael Leung: Michael Leung is currently working as the Vice President of Corporate Operations at HUTCHMED (China) Ltd. He has an MBA from the University of British Columbia and an undergraduate degree from Simon Fraser University.

Chig Fung Cheng: Chig Fung Cheng is currently the Chief Financial Officer & Executive Director at HUTCHMED (China) Ltd. He is also a Director at Hutchison MediPharma Ltd., Sen Medicine Co. Ltd., Hutchison Medipharma (Hong Kong) Ltd., and Hutchison Medipharma (Suzhou) Ltd. Additionally, he is a Member of The Institute of Chartered Accountants in Australia and Chartered Accountants Australia & New Zealand. Previously, he held positions as a Director at Hutchison Healthcare Ltd., Bristol-Myers Squibb (China) Investment Co. Ltd., Sino-American Shanghai Squibb Pharmaceuticals Ltd., Vice President-Finance at Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., and Controller at Nestl (China) Ltd. He also worked as an Auditor at PricewaterhouseCoopers (Australia) and KPMG Beijing. Mr. Cheng completed his undergraduate degree at the University of Adelaide.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Wei Guo Su: Wei Guo Su is currently the CEO, Executive Director & Chief Scientific Officer at HUTCHMED (China) Ltd. since 2022. He is also currently serving as the Chief Scientific Officer & Executive VP at Hutchison MediPharma Ltd. since 2012. Previously, he worked at Pfizer Inc. as the Director-Medicinal Chemistry Department. Dr. Su holds a doctorate degree from Harvard University and an undergraduate degree from Fudan University.

Qing Mei Wang: Qing Mei Wang is currently working as the SVP-Business Development & Strategic Alliances at HUTCHMED (China) Ltd. since 2010 and at Hutchison MediPharma Ltd. since 2012. Previously, Dr. Wang worked as the Head-Asia Discovery Biology at Eli Lilly & Co. Dr. Wang holds a doctorate degree from Purdue University.

Charles Nixon: Charles Nixon is currently the Group General Counsel at HUTCHMED (China) Ltd. He previously worked as Group Senior Legal Counsel at Hutchison Whampoa Ltd., Group Senior Legal Counsel at Hutchison Whampoa Services Ltd., and Senior Legal Counsel at Hutchison 3G UK Ltd. He is a graduate of Middlesex University.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Mark Lee: Mark Lee is currently working as the SVP-Corporate Management & Communications at HUTCHMED (China) Ltd. He completed his undergraduate degree at University College London and holds an MBA from MIT Sloan School of Management.

Yiling Cui: Yiling Cui currently works at HUTCHMED (China) Ltd., as Senior Vice President-Government Affairs. Ms. Cui also formerly worked at Shanghai Asia Pioneer Pharmaceuticals Co. Ltd., as Chief Executive Officer, Sino-American Shanghai Squibb Pharmaceuticals Ltd., as Chairman, Shanghai New Asiatic Pharmaceuticals Co., Ltd., as Chairman, and Shanghai Shyndec Pharmaceutical Co., Ltd., as Vice President. Ms. Cui received her Masters Business Admin degree in 2003 from China Europe International Business School and undergraduate degree in 1987 from Fudan University.

Karen Atkin: Karen Atkin is currently the Chief Operating Officer & Executive Vice President at HUTCHMED (China) Ltd. and is also a Member at The Royal College of Physicians. Previously, she worked as the Country President-Indonesia at AstraZeneca PLC. Dr. Atkin completed her undergraduate degree at University College London and holds an MBA and a doctorate from the Open University of China.

Selina Zhang: Selina Zhang is currently the Senior Vice President-Global Human Resources at HUTCHMED (China) Ltd. She holds a Master's in Business Administration from the International Institute for Management Development and a graduate degree from Capital University of Economics & Business.

Ming Shi: Ming Shi is a member of several professional organizations including the American Society of Clinical Oncology, Inc., the American Association for Cancer Research, the American Society of Hematology, the European Society for Medical Oncology, and the Sino-American Pharmaceutical Professionals Association. Dr. Shi is currently the Chief Medical Officer, EVP, Head-R&D at HUTCHMED (China) Ltd. starting in 2022. Previously, Dr. Shi held positions as a Program Director-Genetics Variation at the National Institutes of Health, an Adjunct Assistant Professor at the University of Michigan Medical School, and the Chief Medical Officer, Head-R&D at Transcenta Holding Ltd. Dr. Shi obtained a doctorate degree from the University of Southern California.

Hong Chen: Hong Chen is currently the General Manager at Hutchison Healthcare Ltd., the General Manager at Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Co., and the Chief Commercial Officer & Executive VP at HUTCHMED (China) Ltd. Mr. Chen has an MBA from Cheung Kong Graduate School of Business and an undergraduate degree from Nanjing Medical University.

和黄药业